Mien-Chie Hung Selected Research

Immune Checkpoint Proteins

1/2022	Development and characterization of anti-galectin-9 antibodies that protect T cells from galectin-9-induced cell death.
1/2022	PD-L1 deficiency sensitizes tumor cells to DNA-PK inhibition and enhances cGAS-STING activation.
12/2020	Pharmacologic Suppression of B7-H4 Glycosylation Restores Antitumor Immunity in Immune-Cold Breast Cancers.
7/2020	The impact of PD-L1 N-linked glycosylation on cancer therapy and clinical diagnosis.
1/2020	Cancer Cell Metabolism Bolsters Immunotherapy Resistance by Promoting an Immunosuppressive Tumor Microenvironment.
1/2018	Juxtacrine Signaling Inhibits Antitumor Immunity by Upregulating PD-L1 Expression.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mien-Chie Hung Research Topics

Disease

293	Neoplasms (Cancer) 10/2022 - 01/2002
132	Breast Neoplasms (Breast Cancer) 01/2022 - 02/2002
65	Neoplasm Metastasis (Metastasis) 10/2021 - 01/2002
43	Carcinogenesis 01/2021 - 06/2002
28	Triple Negative Breast Neoplasms 01/2022 - 09/2009
15	Hepatocellular Carcinoma (Hepatoma) 08/2022 - 11/2002
14	Pancreatic Neoplasms (Pancreatic Cancer) 12/2021 - 03/2002
14	Ovarian Neoplasms (Ovarian Cancer) 01/2020 - 03/2003
13	Adenocarcinoma 01/2022 - 06/2007
13	Prostatic Neoplasms (Prostate Cancer) 01/2021 - 07/2003
12	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2021 - 01/2011
11	Colorectal Neoplasms (Colorectal Cancer) 10/2022 - 11/2002
11	Lung Neoplasms (Lung Cancer) 01/2020 - 11/2004
9	Hypoxia (Hypoxemia) 01/2021 - 04/2005
7	Infections 01/2022 - 10/2002
7	Esophageal Neoplasms (Esophageal Cancer) 12/2015 - 06/2007
6	COVID-19 01/2022 - 01/2020
6	Glioblastoma (Glioblastoma Multiforme) 12/2019 - 02/2009
6	Colonic Neoplasms (Colon Cancer) 01/2018 - 10/2002
5	Carcinoma (Carcinomatosis) 03/2015 - 03/2003
4	Melanoma (Melanoma, Malignant) 01/2021 - 01/2002
4	Genomic Instability 01/2018 - 10/2003
4	Inflammation (Inflammations) 04/2016 - 08/2007

Drug/Important Bio-Agent (IBA)

74	Proteins (Proteins, Gene)FDA Link 01/2022 - 01/2002
41	Phosphotransferases (Kinase)IBA 01/2022 - 02/2002
28	ErbB Receptors (EGF Receptor)IBA 01/2021 - 02/2002
19	Biomarkers (Surrogate Marker)IBA 01/2022 - 06/2004
19	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 11/2002
16	LigandsIBA 01/2022 - 08/2002
16	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2022 - 11/2004
16	Immune Checkpoint InhibitorsIBA 01/2022 - 07/2017
16	Tyrosine Kinase InhibitorsIBA 06/2021 - 11/2009
16	Transcription Factors (Transcription Factor)IBA 01/2020 - 10/2002
15	MicroRNAs (MicroRNA)IBA 01/2018 - 06/2010
14	Biological ProductsIBA 10/2021 - 06/2003
14	Trastuzumab (Herceptin)FDA Link 07/2014 - 10/2002
12	Pharmaceutical PreparationsIBA 01/2021 - 09/2004
11	Monoclonal AntibodiesIBA 01/2022 - 10/2002
11	B7-H1 AntigenIBA 01/2022 - 10/2017
11	Tyrosine (L-Tyrosine)FDA Link 01/2019 - 02/2002
11	Epidermal Growth Factor (EGF)IBA 12/2018 - 11/2006
11	Liposomes (Liposome)IBA 01/2015 - 11/2002
10	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2022 - 02/2016
10	Hormones (Hormone)IBA 01/2021 - 01/2004
10	Small Interfering RNA (siRNA)IBA 04/2018 - 05/2007
10	Paclitaxel (Taxol)FDA LinkGeneric 01/2016 - 10/2002
9	CytokinesIBA 01/2021 - 11/2008
9	Long Noncoding RNAIBA 01/2021 - 11/2014
9	Cadherins (E-Cadherin)IBA 05/2016 - 06/2005
8	RNA (Ribonucleic Acid)IBA 01/2021 - 02/2002
8	LuciferasesIBA 11/2019 - 03/2004
8	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 12/2016 - 10/2002
8	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 10/2016 - 08/2007
7	Ribonucleases (Ribonuclease)IBA 08/2022 - 09/2012
7	Estrogen ReceptorsIBA 01/2021 - 06/2009
7	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2021 - 08/2011
7	Glucose (Dextrose)FDA LinkGeneric 01/2021 - 05/2008
7	Sirolimus (Rapamycin)FDA Link 01/2017 - 02/2004
7	Histones (Histone)IBA 08/2016 - 09/2008
7	NF-kappa B (NF-kB)IBA 04/2012 - 10/2002
7	beta CateninIBA 02/2009 - 10/2002
6	Peptide Hydrolases (Proteases)FDA Link 01/2022 - 06/2014
6	Immune Checkpoint ProteinsIBA 01/2022 - 01/2018
6	tyrosine receptor (receptor, tyrosine)IBA 06/2021 - 11/2009
6	Peptides (Polypeptides)IBA 01/2021 - 10/2002
6	human ERBB2 proteinIBA 01/2021 - 04/2013
5	Programmed Cell Death 1 ReceptorIBA 01/2022 - 12/2018
5	AntibodiesIBA 01/2022 - 04/2004
5	Progesterone Receptors (Progesterone Receptor)IBA 01/2021 - 09/2010
5	Messenger RNA (mRNA)IBA 01/2021 - 10/2005
5	Cetuximab (Erbitux)FDA Link 01/2020 - 12/2015
5	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2020 - 11/2009
5	Interleukin-6 (Interleukin 6)IBA 01/2019 - 09/2011
5	LipidsIBA 01/2019 - 07/2002
5	Ubiquitin-Protein Ligases (Ubiquitin-Protein Ligase)IBA 01/2018 - 05/2012
5	TOR Serine-Threonine KinasesIBA 02/2010 - 10/2004
5	I-kappa B KinaseIBA 10/2009 - 04/2004
5	Glycogen Synthase Kinase 3 betaIBA 02/2009 - 06/2005
4	AntigensIBA 10/2022 - 03/2011
4	Protein Isoforms (Isoforms)IBA 01/2022 - 05/2007
4	Formaldehyde (Formol)FDA Link 01/2022 - 05/2010
4	ParaffinIBA 01/2022 - 08/2011
4	Arginine (L-Arginine)FDA Link 01/2021 - 09/2015
4	Gemcitabine FDA Link 01/2021 - 10/2003
4	Phenobarbital (Luminal)FDA Link 01/2021 - 01/2019
4	Therapeutic UsesIBA 01/2020 - 09/2004
4	Endoplasmic Reticulum Chaperone BiPIBA 01/2020 - 11/2014
4	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2020 - 02/2006
4	EnzymesIBA 01/2020 - 06/2009
4	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 01/2020 - 10/2003
4	AndrogensIBA 01/2020 - 03/2005
4	Lysine (L-Lysine)FDA Link 01/2019 - 09/2008
4	Etoposide (VP 16)FDA LinkGeneric 01/2018 - 07/2007
4	Cisplatin (Platino)FDA LinkGeneric 01/2018 - 02/2013
4	Gefitinib (Iressa)FDA Link 03/2016 - 01/2011
4	Antineoplastic Agents (Antineoplastics)IBA 01/2015 - 10/2002

Therapy/Procedure

103	Therapeutics 10/2022 - 11/2002
27	Drug Therapy (Chemotherapy) 01/2022 - 10/2003
22	Immunotherapy 01/2022 - 10/2017
6	Radiotherapy 10/2022 - 09/2011